Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma

Authors: Dandan Yuan, Hong Zhu, Ting Wang, Yang Zhang, Xin Zheng, Yanjun Qu

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

High-grade serious ovarian carcinoma (HGSOC) is a subtype of ovarian cancer with a different prognosis attributable to genetic heterogeneity. The prognosis of patients with advanced HGSOC requires prediction by genetic markers. This study systematically analyzed gene expression profile data to establish a genetic marker for predicting HGSOC prognosis.

Methods

The RNA-seq data set and information on clinical follow-up of HGSOC were retrieved from Gene Expression Omnibus (GEO) database, and the data were standardized by DESeq2 as a training set. On the other hand, HGSOC RNA sequence data and information on clinical follow-up were retrieved from The Cancer Genome Atlas (TCGA) as a test set. Additionally, ovarian cancer microarray data set was obtained from GEO as the external validation set. Prognostic genes were screened from the training set, and characteristic selection was performed using the least absolute shrinkage and selection operator (LASSO) with 80% re-sampling for 5000 times. Genes with a frequency of more than 2000 were selected as robust biomarkers. Finally, a gene-related prognostic model was validated in both the test and GEO validation sets.

Results

A total of 148 genes were found to be significantly correlated with HGSOC prognosis. The expression profile of these genes could stratify HGSOC prognosis and they were enriched to multiple tumor-related regulatory pathways such as tyrosine metabolism and AMPK signaling pathway. AKR1B10 and ANGPT4 were obtained after 5000-time re-sampling by LASSO regression. AKR1B10 was associated with the metastasis and progression of several tumors. In this study, Cox regression analysis was performed to create a 2-gene signature as an independent prognostic factor for HGSOC, which has the ability to stratify risk samples in all three data sets (p < 0.05). The Gene Set Enrichment Analysis (GSEA) discovered abnormally active REGULATION_OF_AUTOPHAGY and OLFACTORY_TRANSDUCTION pathways in the high-risk group samples.

Conclusion

This study resulted in the creation of a 2-gene molecular prognostic classifier that distinguished clinical features and was a promising novel prognostic tool for assessing the prognosis of HGSOC. RiskScore was a novel prognostic model which might be effective in guiding accurate prognosis of HGSOC.
Appendix
Available only for authorised users
Literature
2.
go back to reference Kobel M, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.PubMedCrossRef Kobel M, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.PubMedCrossRef
3.
go back to reference Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi. 2014;43(10):649–50.PubMed Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi. 2014;43(10):649–50.PubMed
5.
go back to reference Markman M, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21(13):2460–5.PubMedCrossRef Markman M, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21(13):2460–5.PubMedCrossRef
7.
go back to reference Coleman MP, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.PubMedPubMedCentralCrossRef Coleman MP, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.PubMedPubMedCentralCrossRef
11.
go back to reference Spentzos D, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700–10.PubMedCrossRef Spentzos D, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700–10.PubMedCrossRef
12.
go back to reference Crijns AP, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2): e24.PubMedCrossRef Crijns AP, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2): e24.PubMedCrossRef
13.
14.
go back to reference Jazaeri AA, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11(17):6300–10.PubMedCrossRef Jazaeri AA, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11(17):6300–10.PubMedCrossRef
15.
go back to reference Tomar T, et al. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 2017;15(1):116.PubMedPubMedCentralCrossRef Tomar T, et al. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 2017;15(1):116.PubMedPubMedCentralCrossRef
16.
go back to reference Liu G, et al. Seven genes based novel signature predicts clinical outcome and platinum sensitivity of high grade IIIc serous ovarian carcinoma. Int J Biol Sci. 2018;14(14):2012–22.PubMedPubMedCentralCrossRef Liu G, et al. Seven genes based novel signature predicts clinical outcome and platinum sensitivity of high grade IIIc serous ovarian carcinoma. Int J Biol Sci. 2018;14(14):2012–22.PubMedPubMedCentralCrossRef
17.
go back to reference Ducie J, et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017;8(1):990.PubMedPubMedCentralCrossRef Ducie J, et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017;8(1):990.PubMedPubMedCentralCrossRef
19.
go back to reference Vathipadiekal V, et al. Creation of a human secretome: a novel composite library of human secreted proteins: validation using ovarian cancer gene expression data and a virtual secretome array. Clin Cancer Res. 2015;21(21):4960–9.PubMedCrossRef Vathipadiekal V, et al. Creation of a human secretome: a novel composite library of human secreted proteins: validation using ovarian cancer gene expression data and a virtual secretome array. Clin Cancer Res. 2015;21(21):4960–9.PubMedCrossRef
20.
go back to reference Guo JC, et al. Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma. Cancer Commun (Lond). 2018;38(1):4.PubMed Guo JC, et al. Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma. Cancer Commun (Lond). 2018;38(1):4.PubMed
21.
go back to reference Moreno-Betancur M, et al. Survival analysis with time-dependent covariates subject to missing data or measurement error: multiple imputation for joint modeling (MIJM). Biostatistics. 2018;19(4):479–96.PubMedCrossRef Moreno-Betancur M, et al. Survival analysis with time-dependent covariates subject to missing data or measurement error: multiple imputation for joint modeling (MIJM). Biostatistics. 2018;19(4):479–96.PubMedCrossRef
22.
go back to reference Lee TF, et al. Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer. PLoS ONE. 2014;9(2): e89700.PubMedPubMedCentralCrossRef Lee TF, et al. Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer. PLoS ONE. 2014;9(2): e89700.PubMedPubMedCentralCrossRef
23.
go back to reference Zhang JX, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–306.PubMedCrossRef Zhang JX, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–306.PubMedCrossRef
24.
go back to reference Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27 (quiz 3699).PubMedPubMedCentralCrossRef Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27 (quiz 3699).PubMedPubMedCentralCrossRef
25.
26.
go back to reference Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin. Epigenetics. 2019;11(1):123.CrossRef Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin. Epigenetics. 2019;11(1):123.CrossRef
29.
go back to reference Wang R, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma. 2019;66(3):343–9.PubMedCrossRef Wang R, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma. 2019;66(3):343–9.PubMedCrossRef
30.
go back to reference Benvenuto G, et al. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. Int J Cancer. 2020;147(2):565–74.PubMedCrossRef Benvenuto G, et al. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. Int J Cancer. 2020;147(2):565–74.PubMedCrossRef
31.
go back to reference Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.PubMedCrossRef Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.PubMedCrossRef
32.
go back to reference Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.PubMedCrossRef Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.PubMedCrossRef
34.
go back to reference Bhutiani N, et al. Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making. J Am Coll Surg. 2018;226(4):406-412 e1.PubMedCrossRef Bhutiani N, et al. Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making. J Am Coll Surg. 2018;226(4):406-412 e1.PubMedCrossRef
35.
go back to reference Wang SY, et al. Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. 2018;36(16):1619–27.PubMedPubMedCentralCrossRef Wang SY, et al. Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. 2018;36(16):1619–27.PubMedPubMedCentralCrossRef
36.
go back to reference Kopetz S, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015;20(2):127–33.PubMedPubMedCentralCrossRef Kopetz S, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015;20(2):127–33.PubMedPubMedCentralCrossRef
37.
go back to reference Tan IB, Tan P. Genetics: an 18-gene signature [ColoPrint(R)] for colon cancer prognosis. Nat Rev Clin Oncol. 2011;8(3):131–3.PubMedCrossRef Tan IB, Tan P. Genetics: an 18-gene signature [ColoPrint(R)] for colon cancer prognosis. Nat Rev Clin Oncol. 2011;8(3):131–3.PubMedCrossRef
38.
go back to reference Maak M, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053–8.PubMedCrossRef Maak M, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053–8.PubMedCrossRef
39.
go back to reference Ding Q, et al. A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer. Aging (Albany NY). 2020;12(6):4879–95.PubMedCrossRef Ding Q, et al. A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer. Aging (Albany NY). 2020;12(6):4879–95.PubMedCrossRef
41.
go back to reference van Weverwijk A, et al. Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 2019;10(1):2698.PubMedPubMedCentralCrossRef van Weverwijk A, et al. Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 2019;10(1):2698.PubMedPubMedCentralCrossRef
42.
go back to reference Ahmed SMU, et al. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett. 2019;17(1):773–80.PubMed Ahmed SMU, et al. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett. 2019;17(1):773–80.PubMed
43.
go back to reference Liu W, et al. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model. Acta Biomater. 2019;91:195–208.PubMedCrossRef Liu W, et al. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model. Acta Biomater. 2019;91:195–208.PubMedCrossRef
44.
go back to reference Han C, et al. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett. 2018;16(6):7123–30.PubMedPubMedCentral Han C, et al. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett. 2018;16(6):7123–30.PubMedPubMedCentral
45.
go back to reference Torres-Mena JE, et al. Aldo-keto reductases as early biomarkers of hepatocellular carcinoma: a comparison between animal models and human HCC. Dig Dis Sci. 2018;63(4):934–44.PubMedCrossRef Torres-Mena JE, et al. Aldo-keto reductases as early biomarkers of hepatocellular carcinoma: a comparison between animal models and human HCC. Dig Dis Sci. 2018;63(4):934–44.PubMedCrossRef
46.
go back to reference DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers (Basel). 2019;11(4):486.PubMedCrossRef DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers (Basel). 2019;11(4):486.PubMedCrossRef
47.
go back to reference Ko HH, et al. Increased salivary AKR1B10 level: association with progression and poor prognosis of oral squamous cell carcinoma. Head Neck. 2018;40(12):2642–7.PubMedCrossRef Ko HH, et al. Increased salivary AKR1B10 level: association with progression and poor prognosis of oral squamous cell carcinoma. Head Neck. 2018;40(12):2642–7.PubMedCrossRef
48.
go back to reference Ohashi T, et al. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res. 2013;11(12):1554–63.PubMedCrossRef Ohashi T, et al. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res. 2013;11(12):1554–63.PubMedCrossRef
49.
go back to reference Brunckhorst MK, et al. Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol. 2014;184(8):2285–96.PubMedPubMedCentralCrossRef Brunckhorst MK, et al. Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol. 2014;184(8):2285–96.PubMedPubMedCentralCrossRef
Metadata
Title
Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma
Authors
Dandan Yuan
Hong Zhu
Ting Wang
Yang Zhang
Xin Zheng
Yanjun Qu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01376-0

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue